The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation ...

Sobi® (STO: SOBI) together with the World Federation of Hemophilia (WFH) and Sanofi, through its philanthropic organisation Foundation S, announced the signing of a contract providing support to the ...

Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistanceSTOCKHOLM, April 25, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) together ...

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Financial report dates in 2026 Stora Enso Oyj will publish four interim reports in 2026. The publication dates for financial information will be as follows: Financial Statement release for 2025 4 ...

The Canadian Cancer Society (CCS) closed the 32nd edition of its prestigious Montreal Daffodil Ball by raising a historic amount of $3,413,908. Presented under the theme Prospective, the Ball ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of treatment administered every two months for patients with the rare blood clotting ...

Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER.

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. Into this crowded treatment landscape comes another new medicine as the FDA has signed off ...

Sanofi's Qfitlia, approved a few days ago by the FDA, offers a competitive edge in the hemophilia market with fewer injections and broader applicability than rivals. Despite Qfitlia's promising ...